122 related articles for article (PubMed ID: 36733163)
21. [A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].
Kawai H; Sugimoto R; Miyauchi S; Yoshida R; Waki N; Hirayama S; Ishizaki M; Nishi H; Yamashita K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1957-9. PubMed ID: 25731388
[TBL] [Abstract][Full Text] [Related]
22. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of Bevacizumab in Combination with Weekly Paclitaxel for Locally Advanced Breast Cancer].
Sugimoto H; Orita F; Kume Y; Baba H; Sato Y; Hoshino N; Nishioka Y
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1424-1426. PubMed ID: 28133011
[TBL] [Abstract][Full Text] [Related]
25. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
[TBL] [Abstract][Full Text] [Related]
26. [Bevacizumab plus Paclitaxel Therapy Was Effective for Metastatic Breast Cancer with Dysphagia Due to Mediastinal Lymph Node Metastasis-A Case Report].
Kodera A; Inoue H; Ogura K; Sakaguchi S; Yukawa H; Matsuoka A; Tanaka N; Kinoshita J; Yoshimatsu K; Naritaka Y; Hirano A
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2276-2278. PubMed ID: 30692436
[TBL] [Abstract][Full Text] [Related]
27. [Axillary Arterial Bleeding with Administration of Bevacizumab plus Paclitaxel in a Patient with Recurrent Breast Cancer-A Case Report].
Tsuruda Y; Masuda T; Hayashi N; Noda M; Otsu H; Kuroda Y; Eguchi H; Tanaka F; Natsugoe S; Mimori K
Gan To Kagaku Ryoho; 2020 Jan; 47(1):117-119. PubMed ID: 32381877
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
30. [A Case Report of Surgery and Chemotherapy for a Patient with Rapidly Progressing Breast Cancer during Pregnancy].
Hazama Y; Nakai Y; Sugawara S; Nomura T; Matsumoto K; Matsumoto R; Sugihara M; Ishida T; Murata S; Murata T; Nakamura T; Moriya T; Kurebayashi J; Shimoya K
Gan To Kagaku Ryoho; 2018 May; 45(5):847-850. PubMed ID: 30026449
[TBL] [Abstract][Full Text] [Related]
31. [Third- and Fourth-Line Chemotherapies including Paclitaxel and Bevacizumab for Metastatic Breast Cancer].
Sakamoto M; Nio Y; Imai S; Uesugi K; Tamaoki M; Tamaoki M
Gan To Kagaku Ryoho; 2017 Jul; 44(7):579-584. PubMed ID: 28790261
[TBL] [Abstract][Full Text] [Related]
32. [A long-surviving case of HER2-positive breast cancer with brain metastasis treated by multidisciplinary therapy].
Sugimoto H; Nakagawa T; Sato T; Nagahara M; Ishiba T; Kasahara M; Kawachi H; Kubota K; Sugihara K
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2071-3. PubMed ID: 23267980
[TBL] [Abstract][Full Text] [Related]
33. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
34. [A patient with primary breast cancer who responded remarkably well to neoadjuvant chemotherapy with FEC100 followed by Abraxane].
Yoshibayashi H; Ishiguro H; Kawaguchi K; Yamoto M; Nishimura T; Yamada H; Namura M; Nishio N; Nakamura K; Shimada K; Ono K; Kato H
Gan To Kagaku Ryoho; 2013 May; 40(5):627-9. PubMed ID: 23863587
[TBL] [Abstract][Full Text] [Related]
35. [A case of advanced breast cancer successfully treated with paclitaxel and toremifene therapy].
Sakurai K; Enomoto K; Tani M; Kitajima A; Amano S; Shiono M
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2219-21. PubMed ID: 19106576
[TBL] [Abstract][Full Text] [Related]
36. [Chemotherapy-Resistant Breast Cancer and Carcinomatous Pleuritis Successfully Treated with Abemaciclib plus Letrozole Therapy].
Nozaki Y; Yamamuro M; Tanaka N; Kamo N; Konishi J
Gan To Kagaku Ryoho; 2023 Apr; 50(4):477-479. PubMed ID: 37066461
[TBL] [Abstract][Full Text] [Related]
37. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
Yamamoto Y; Yamashiro H; Schneeweiss A; Müller V; Gluz O; Klare P; Aktas B; Magdolna D; Büdi L; Pikó B; Mangel L; Toi M; Morita S; Ohno S
Breast Cancer; 2023 Jan; 30(1):88-100. PubMed ID: 36057014
[TBL] [Abstract][Full Text] [Related]
39. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Yamamoto Y; Yamashiro H; Toh U; Kondo N; Nakamura R; Kashiwaba M; Takahashi M; Tsugawa K; Ishikawa T; Nakayama T; Ohtani S; Takano T; Fujisawa T; Toyama T; Kawaguchi H; Mashino K; Tanino Y; Morita S; Toi M; Ohno S
Breast Cancer; 2021 Jan; 28(1):145-160. PubMed ID: 32715420
[TBL] [Abstract][Full Text] [Related]
40. [A Case of Locally Advanced Breast Cancer Successfully Treated with Local Control That Achieved a Pathological Complete Response after Bevacizumab and Paclitaxel Combination Chemotherapy].
Ueno N; Suzushino S; Kubo T; Abe A; Ito J; Yasuda M; Kato H
Gan To Kagaku Ryoho; 2017 Nov; 44(11):1033-1035. PubMed ID: 29138383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
